To study the results of hormonal treatment along with chemotherapy in previously treated hormone positive metastatic breast cancer patients.
Not Applicable
- Conditions
- Health Condition 1: C50- Malignant neoplasm of breast
- Registration Number
- CTRI/2022/01/039242
- Lead Sponsor
- ot applicable
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All patients above 18 yrs who have ER and/or PR positive and HER2 negative metastatic breast cancer and who have received a combination of chemotherapy and endocrine therapy between January
2016 and December 2020.
Exclusion Criteria
Patients who have HER2 positive tumors.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.To analyze the overall survival (OS) of included patients <br/ ><br>2 To analyze the progression-free survival(PFS) of included <br/ ><br>patientsTimepoint: Post 6 months and 12 months of treatment completion.
- Secondary Outcome Measures
Name Time Method To analyze the time-on-treatment of the combination of <br/ ><br>chemo and endocrine therapy for included patients <br/ ><br>9.3.2 To assess the toxicities from the combination of <br/ ><br>chemotherapy and endocrine therapy, in included patients. <br/ ><br>9.3.2 To analyze the best overall response (complete response <br/ ><br>plus partial response, stable response or disease progression) to <br/ ><br>combination chemotherapy and endocrine therapyTimepoint: Post 6 months and 12 months of treatment completion.